<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HE71B61EE00224F98AEAB13D112305EFA" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 2562 IH: Making Pharmaceutical Markets More Competitive Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-05-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 2562</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170519">May 19, 2017</action-date><action-desc><sponsor name-id="K000376">Mr. Kelly of Pennsylvania</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To improve access to prescription drugs.</official-title></form>
	<legis-body id="HB1EFC537E6A045CDBC6389C6C98F1F67" style="OLC">
 <section id="HF0191E8BD3254E80B4F0909FA1CAA35A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Making Pharmaceutical Markets More Competitive Act</short-title></quote>.</text> </section><title id="HFB93F42C81504786A1953DE1D467EDFA" style="OLC"><enum>I</enum><header>Removing regulatory barriers to competition </header> <section id="HA331756DD4134DAA8D4EE15C1D3C4928"><enum>101.</enum><header>Improving access to generic drugs</header><text display-inline="no-display-inline">Section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="HB66549D2E1BD48CBB0CA5A8A3C6EF763" style="OLC">
					<paragraph id="H69DC44A514034CEBADE4119993EA8344" indent="up1"><enum>(11)</enum>
 <subparagraph commented="no" display-inline="yes-display-inline" id="H6F6F736597E4435BB8BF56AD5754A40F"><enum>(A)</enum><text>The Secretary shall prioritize the review of, and act within 240 calendar days of the date of the submission of, an original abbreviated new drug application submitted for review under this subsection, or on a supplement to such an application, that is for a drug—</text>
 <clause id="H714B3D7775D7423EBB02E40AAF9434ED" indent="up1"><enum>(i)</enum><text>for which there are not more than 3 approved drugs listed under paragraph (7), except that the review of an application submitted more than 30 months in advance of the last applicable expiration date for a patent for which a certification under paragraph (2)(A)(vii)(III) has been submitted, or of the expiration date for an applicable period of exclusivity under this Act, will not be expedited; or</text>
 </clause><clause id="HDB03A6E1DD5241A984763B71D2FEBE30" indent="up1"><enum>(ii)</enum><text>that has been included on the list under section 506E.</text> </clause></subparagraph><subparagraph id="H1B6DA0A2EB854DD98361B1DFB496A4DB" indent="up1"><enum>(B)</enum><text>The Secretary shall require the applicant, not later than 60 days prior to the submission of an application described in subparagraph (A), to provide complete, accurate information regarding facilities involved in manufacturing processes and testing, including facilities in corresponding Type II active pharmaceutical ingredients drug master files submitted with an application and sites or organizations involved in bioequivalence and clinical studies used to support the application, in order to make a determination regarding whether an inspection of an establishment is necessary.</text>
 </subparagraph><subparagraph id="H4DB443ACDD94492183302A37B25B34D8" indent="up1"><enum>(C)</enum><text>The Secretary may expedite an inspection or reinspection under section 704 of an establishment that proposes to manufacture a drug described in subparagraph (A).</text>
 </subparagraph><subparagraph id="H2C9DE8CFDA2A42F99A98E83D0B734A4A" indent="up1"><enum>(D)</enum><text>Nothing in this paragraph shall prevent the Secretary from prioritizing the review of other applications as the Secretary determines appropriate.</text>
 </subparagraph></paragraph><paragraph id="HCC566EC57A914CAFB2709F02499B7E12" indent="up1"><enum>(12)</enum><text>The Secretary shall provide review status updates to applicants regarding applications under this subsection, as appropriate, including when the application is awaiting final regulatory action by the office charged with review.</text>
 </paragraph><paragraph id="HAEC8F38E093242CCBE367F3D992806DF" indent="up1"><enum>(13)</enum><text>The Secretary shall publish on the Internet website of the Food and Drug Administration a list of all drugs approved under subsection (b) for which all patents and periods of exclusivity under this Act have expired. Such list shall be updated at least once every 180 days.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
			</section><section id="H0E58519FF5A24525B17FE5E1F6D687DE"><enum>102.</enum><header>Reporting on pending generic drug applications, priority review applications, and inspections</header>
 <subsection id="HF87D5A2961D94C0094C1C9608485C254"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 180 calendar days after the date of enactment of this Act, and quarterly thereafter until October 1, 2022, the Secretary of Health and Human Services (referred to in this section as the <quote>Secretary</quote>) shall post on the Internet website of the Food and Drug Administration a report that provides—</text>
 <paragraph id="H0EF61251F95E480F97CED1266057A77A"><enum>(1)</enum><text display-inline="yes-display-inline">the number of applications filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) awaiting action by the applicant, including such applications that were filed prior to October 1, 2014;</text>
 </paragraph><paragraph id="HBE6179E40B8F43D7A6B09E9EA1CA4D4F"><enum>(2)</enum><text>the number of applications filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) awaiting action by the Secretary, including such applications that were filed prior to October 1, 2014;</text>
 </paragraph><paragraph id="HB866C5D2F078430EB2C3D0805A2889F0"><enum>(3)</enum><text>the number of applications filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) and prior approval supplements withdrawn in each month covered by the report;</text>
 </paragraph><paragraph id="H6686A631D3144F09B51699BDB7D09637"><enum>(4)</enum><text display-inline="yes-display-inline">the mean and median approval and tentative approval times for applications covered by the report;</text> </paragraph><paragraph id="HA88EF031284A417D82750D81D802309C"><enum>(5)</enum><text>the number of applications described in paragraphs (1), (2), and (3) that are subject to priority review; and</text>
 </paragraph><paragraph id="H285FACB717F94099841A9996B40F7470"><enum>(6)</enum><text>the number of such applications on which the Secretary has taken action pursuant to section 506H(b) of the Federal Food, Drug, and Cosmetic Act, as added by section 101.</text>
					</paragraph></subsection><subsection id="H8B2D3BBB19ED4C818C9411DDC094D64E"><enum>(b)</enum><header>Annual report on priority review applications</header>
 <paragraph id="H7BC11C4A44AC482384F02823A51D8F49"><enum>(1)</enum><header>In general</header><text>The Secretary shall submit to the Committee on Health, Education, Labor, and Pensions and the Special Committee on Aging of the Senate and the Committee on Energy and Commerce of the House of Representatives an annual report, not later than March 31 of each year, on the following:</text>
 <subparagraph id="H5321398922ED46C1A8A8E6CC8CF2D915"><enum>(A)</enum><text>The number of applications filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) that are subject to priority review during the most recent calendar year and are awaiting action by the applicant.</text>
 </subparagraph><subparagraph id="HA1E634EF9B5C439A9EC005C1D7F84602"><enum>(B)</enum><text>The number of applications filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) that are subject to priority review during the most recent calendar year and are awaiting action by the Secretary.</text>
 </subparagraph><subparagraph id="H0607E1A3D794478C84F89878A0A1D5E2"><enum>(C)</enum><text>The number of applications filed under section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) that are subject to priority review during the most recent calendar year and have been approved by the Secretary.</text>
 </subparagraph><subparagraph id="H8076E6BDF43742F6BF6D07FD8D8BF2B5"><enum>(D)</enum><text>For each of subparagraphs (A) through (C), the number of such applications—</text> <clause id="H14063383CFA247E0A89F033F25CF303C"><enum>(i)</enum><text>for which there are not more than 3 approved drugs listed under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(7)</external-xref>); and</text>
 </clause><clause id="HFA2D8202A2414AA4A3A93DC5878E7CC5"><enum>(ii)</enum><text>the number of such applications that are for a drug on the drug shortage list under section 506E of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356e">21 U.S.C. 356e</external-xref>).</text>
 </clause></subparagraph></paragraph></subsection><subsection id="H09994E4D11C54695825B65F7959AB022"><enum>(c)</enum><header>Annual report on inspections</header><text>Not later than March 1 of each year, the Secretary shall post on the Internet website of the Food and Drug Administration—</text>
 <paragraph id="H48BF5EF9548F42CE93B9DF0DEEAFEA69"><enum>(1)</enum><text>the average and median amount of time, following a request by staff of the Food and Drug Administration reviewing an application or report submitted under an applicable section described in subparagraph (A), (B), or (C), to schedule and complete inspections of facilities necessary for—</text>
 <subparagraph id="H19870298CB3445659D156161D17E07DE"><enum>(A)</enum><text>approval of a drug under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>);</text> </subparagraph><subparagraph id="H22B47FBA06BC48F68B598B08AEDB4578"><enum>(B)</enum><text>approval of a device under section 515 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360e">21 U.S.C. 360e</external-xref>); and</text>
 </subparagraph><subparagraph id="H3D3A767660124549B3E237576F6A5C93"><enum>(C)</enum><text>clearance of a device under section 510(k) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(k)</external-xref>); and</text> </subparagraph></paragraph><paragraph id="HA87FEDC289CB4F6AB19ACA806CF0D555"><enum>(2)</enum><text>the average and median amount of time to schedule and complete for-cause inspections of facilities of drugs and devices.</text>
					</paragraph></subsection></section></title><title id="H8DE3EFBEDA9343F88C80DBED6F9F4EDC" style="OLC"><enum>II</enum><header>Incentivizing competition</header>
 <section id="H4463DA9E79904B128D6CD3989867186F"><enum>201.</enum><header>Expediting generic competition</header><text display-inline="no-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351</external-xref> et seq.) is amended by inserting after section 506G the following:</text>
				<quoted-block display-inline="no-display-inline" id="H4A0D629879BB404494594A7982B997EB" style="OLC">
					<section id="HDF6BB736AEFE411BB36F33DAD6FF17ED"><enum>506H.</enum><header>Expediting generic drug development</header>
 <subsection id="H616E5EC0F48E449AB0B09706F74DBE03"><enum>(a)</enum><header>In general</header><text>The Secretary shall, at the request of an applicant, expedite the development and review of an application under subsection (j) of section 505 for a drug—</text>
 <paragraph id="H2EC632240C0F43CB9D96FED7AEF35C1E"><enum>(1)</enum><text>for which there are not more than 3 approved drug products listed under section 505(j)(7); or</text> </paragraph><paragraph id="H67C4B2525BD2469690C36989301249E8"><enum>(2)</enum><text>that is included on the list under section 506E.</text>
 </paragraph></subsection><subsection id="H931A65CFA2D24F87B3AC1535606774A9"><enum>(b)</enum><header>Request from sponsors</header><text>A request to expedite the development and review of an application under subsection (a) shall be submitted by the applicant prior to the submission of such application.</text>
 </subsection><subsection id="H5AEE8D68DBF248E1B941196320E410D4"><enum>(c)</enum><header>Other applications</header><text>Nothing in this section shall prevent the Secretary from expediting the development and review of other applications as the Secretary determines appropriate.</text>
 </subsection><subsection id="H33C571811F7D40A68CC2EE935542904E"><enum>(d)</enum><header>Additional communication</header><text>The Secretary shall take such actions as are appropriate to expedite the development and review of the application for approval of a drug described in subsection (a), including, as appropriate—</text>
 <paragraph id="H283E1AD6C0BA47DD9B8AC54367BDD7B9"><enum>(1)</enum><text>holding meetings with the sponsor and the review team throughout the development of the drug prior to submission of the application;</text>
 </paragraph><paragraph id="H4E8AD0A3ED2C43C78E9ACFF95693D5FB"><enum>(2)</enum><text>providing timely advice to, and interactive communication with, the sponsor regarding the development of the application to ensure that the collection of nonclinical and clinical data necessary for approval is as efficient as practicable;</text>
 </paragraph><paragraph id="H77413B8BB8534D6FBA1A2B8E527912B4"><enum>(3)</enum><text>in the case of a complex product, assigning a cross-disciplinary project lead for the review team to facilitate an efficient review of the development program and application, including manufacturing inspections; and</text>
 </paragraph><paragraph id="H8B85F29DBF624C01B6D5401D54EA7806"><enum>(4)</enum><text>in the case of a complex product, including drug-device combinations, involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review.</text>
 </paragraph></subsection><subsection id="H39337E68BE9948FFB0C678DC20AEA5BF"><enum>(e)</enum><header>Reporting requirement</header><text>A sponsor of a drug expedited under this section shall report to the Secretary, one year following approval of an application under section 505(j), on whether the approved drug has been marketed in interstate commerce since approval.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
 </section><section id="H1336E32706F845E0A55356136FB2FD82"><enum>202.</enum><header>List of generic drugs with limited competition</header><text display-inline="no-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351</external-xref> et seq.) is amended by inserting after section 506H, as added by section 201, the following:</text>
				<quoted-block display-inline="no-display-inline" id="H046B100282BD4A0785638CDD1FEACA3C" style="OLC">
					<section id="HB875D06683784E5BA8A18DAF22D61314"><enum>506I.</enum><header>Drug listing</header>
 <subsection id="H7B397BE2939649549E6A8757F410F293"><enum>(a)</enum><header>Removal, withdrawal, or transfer</header><text>The holder of an application approved under subsection (b) or (j) of section 505 shall notify the Secretary within 180 days of removing the drug that is the subject of such application from interstate commerce, withdrawing such approved application, or transferring such approved application, and a reason for such removal, withdrawal, or transfer. If compliance with this subsection within such 180-day period is not practicable, then the holder shall comply as soon as practicable. The Secretary shall cross-reference information listed pursuant to section 506C where applicable to avoid duplicative reporting. Notification to the Secretary by a manufacturer in accordance with section 506C(a) shall be deemed to be in compliance with this section.</text>
						</subsection><subsection id="H82EF7FCF9FA242DEA42D35B2AB1D863D"><enum>(b)</enum><header>Drugs with limited competition</header>
 <paragraph id="H9724B82FF03E480CA1A99B136D7E2C1D"><enum>(1)</enum><header>Information</header><text>The Secretary shall—</text> <subparagraph id="H3C1B2FEFE2EC40AF9BE6BE9F1D89F0CA"><enum>(A)</enum><text>maintain information with respect to applications approved under section 505(j); and</text>
 </subparagraph><subparagraph id="HADA477F85E18485CAB94CD153CD5DB42"><enum>(B)</enum><text>publish on the Internet website of the Food and Drug Administration such information under subparagraph (A) with respect to drugs for which there are 3 or fewer application holders; and</text>
 </subparagraph><subparagraph id="HF88178F0F6694807B4312D051FB30A2B"><enum>(C)</enum><text>update the information published pursuant to subparagraph (B) every 180 days.</text> </subparagraph></paragraph><paragraph id="H53741F93A67A4F12BFFB52DB4EBED047"><enum>(2)</enum><header>Contents</header><text>The public information maintained and published under paragraph (1)(B) shall include—</text>
 <subparagraph id="H7B76514E6E204B40BC819953DBED25B9"><enum>(A)</enum><text>the name of the drug, name of the holder of the approved application, and the marketing status for each drug; and</text>
 </subparagraph><subparagraph id="H0957722D0352471780271FC241DE2745"><enum>(B)</enum><text>an indication of whether the Secretary considers the drug to be for the treatment or prevention of a serious disease or medical condition, for which there is no alternative drug that is judged by medical professionals to be an adequate substitute available in adequate supply.</text>
 </subparagraph></paragraph></subsection><subsection id="HD8FAF2B530F547319562CF02D6EC5D2C"><enum>(c)</enum><header>Public health exception</header><text>The Secretary may choose not to make information collected under this section publicly available if the Secretary determines that disclosure of such information would adversely affect the public health.</text>
 </subsection><subsection id="H0B667FF6E9B54248A097EDB781EFBD28"><enum>(d)</enum><header>Notification</header><text>When the Secretary first publishes the information under subsection (b), the Secretary shall notify relevant Federal agencies, including the Centers for Medicare &amp; Medicaid Services and the Federal Trade Commission, that the information has been published and will be updated regularly.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
			</section><section id="H45498B593565405ABB8E13BDDA341C69"><enum>203.</enum><header>Suitability petitions</header>
 <subsection id="HA4C13DC6837B4A8A857B0E7D1E2C7934"><enum>(a)</enum><header>In general</header><text>It is the sense of the Senate that the Food and Drug Administration shall meet the requirement under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(5)(C)</external-xref>) and section 314.93(e) of title 21, Code of Federal Regulations, of responding to suitability petitions within 90 days of submission.</text>
 </subsection><subsection id="HE4A1AD0030F64209A752EE8B525423F3"><enum>(b)</enum><header>Report</header><text>The Secretary of Health and Human Services shall include in the annual reports under section 102(b)—</text>
 <paragraph id="H855359C59D9C46E89AAF19E31FC94DA8"><enum>(1)</enum><text>the number of pending petitions under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(5)(C)</external-xref>); and</text>
 </paragraph><paragraph id="HDD49B2102FE149159547B31AC0597D7D"><enum>(2)</enum><text>the number of such petitions pending a substantive response for more than 180 days from the date of receipt.</text>
 </paragraph></subsection></section><section commented="no" id="HF4376E3628D04182AB5293D25C2DCA71"><enum>204.</enum><header>Inspections</header><text display-inline="no-display-inline">Section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>), as amended by section 101, is further amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="HB37446620DAA44BA834EE605E863F71C" style="OLC">
 <paragraph commented="no" id="HBC73C14061664B418AAC85D50D455091" indent="up1"><enum>(14)</enum><text>If the Secretary issues feedback pursuant to section 704(b)(2) with respect to information submitted in response to a report under section 704(b)(1), and a report that was issued under section 704(b)(1) is the only obstacle to approval of an application under this subsection or the Secretary determines that the public health benefit of approving an application under this subsection outweighs any risk to public health, the Secretary shall, within 45 days of notification by the applicant that necessary changes have been made to the establishment to address any findings or deficiencies identified previously by the Secretary—</text>
 <subparagraph commented="no" id="H15031097043C4D0F8699A960AF3DA07C"><enum>(A)</enum><text>re-inspect the establishment with respect to which the report was issued; or</text> </subparagraph><subparagraph commented="no" id="H64ACC268190F464EBF161DC5E46680EF"><enum>(B)</enum><text>make a determination regarding the response to such report and review of such application.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
			</section></title></legis-body></bill>


